Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma

Nivedita Arora, Arjun Gupta, Navid Sadeghi

Research output: Contribution to journalArticle

Abstract

Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.

Original languageEnglish (US)
Article numberbcr-2017-222063
JournalBMJ Case Reports
Volume2017
DOIs
StatePublished - 2017

Fingerprint

Combination Drug Therapy
HIV
Drug Therapy
Highly Active Antiretroviral Therapy
Vincristine
Etoposide
Prednisone
Rectum
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Autoimmune Diseases
Acquired Immunodeficiency Syndrome
Pain
Bortezomib
Plasmablastic Lymphoma
Liver

Keywords

  • HIV / AIDS
  • malignant and benign haematology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. / Arora, Nivedita; Gupta, Arjun; Sadeghi, Navid.

In: BMJ Case Reports, Vol. 2017, bcr-2017-222063, 2017.

Research output: Contribution to journalArticle

@article{777fa919fc9e47fb94055d2fbdc1b43f,
title = "Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma",
abstract = "Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.",
keywords = "HIV / AIDS, malignant and benign haematology",
author = "Nivedita Arora and Arjun Gupta and Navid Sadeghi",
year = "2017",
doi = "10.1136/bcr-2017-222063",
language = "English (US)",
volume = "2017",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma

AU - Arora, Nivedita

AU - Gupta, Arjun

AU - Sadeghi, Navid

PY - 2017

Y1 - 2017

N2 - Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.

AB - Plasmablastic lymphoma (PBL) is an aggressive form of non-Hodgkin's lymphoma (NHL) classically seen in patients infected with the human immunodeficiency virus, but can also be seen in other immunocompromised states such as transplant recipients, autoimmune diseases and the elderly. PBL is generally associated with a poor prognosis despite chemotherapy. There is evidence supporting the use of bortezomib in combination with standard chemotherapy to achieve durable responses in patients with PBL. We describe a patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum. He was diagnosed with stage IVA PBL with anorectal, nodal, calvarial and hepatic involvement. Along with highly active antiretroviral therapy, he was treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) plus bortezomib resulting in durable complete remission 30 months after diagnosis.

KW - HIV / AIDS

KW - malignant and benign haematology

UR - http://www.scopus.com/inward/record.url?scp=85032229898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032229898&partnerID=8YFLogxK

U2 - 10.1136/bcr-2017-222063

DO - 10.1136/bcr-2017-222063

M3 - Article

C2 - 28993364

AN - SCOPUS:85032229898

VL - 2017

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

M1 - bcr-2017-222063

ER -